Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Litigation Details for Novozymes A/S v. Genencor International, Inc. (D. Del. 2005)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Novozymes A/S v. Genencor International, Inc. (D. Del. 2005)

Docket   Start Trial Date Filed 2005-03-15
Court District Court, D. Delaware Date Terminated 2007-04-17
Cause 35:271 Patent Infringement Assigned To Kent A. Jordan
Jury Demand None Referred To Mary Pat Thynge
Patents 10,066,019; 6,159,687; 6,537,746; 6,541,207; 9,081,016; 9,127,013
Attorneys Donald E. Reid; George E. Hykal; Joseph R. Robinson; Josy W. Ingersoll; Karen Elizabeth Keller; Kevin L. Reiner; Robert C. Sullivan; Robert Schaffer; Samuel S. Woodley; Steven E. Lipman
Firms Morris, Nichols, Arsht & Tunnell; Shaw Keller LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Novozymes A/S v. Genencor International, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in Novozymes A/S v. Genencor International, Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Novozymes A/S v. Genencor International, Inc. (D. Del. 2005)

Date Filed Document No. Description Snippet Link To Document
2006-04-21 118 POST Trial Brief residues in a sequence alignment TE-IOO, A7040 at 65:10-66:19; A5142:5-23; A5639:5-18. “For numbering” means…the ‘031 Patent ........................ 22 2. Spezyme Ethyl Infn`nges Claim 3 of the ‘031 Patent ......…Infringes Claim 5 of the ‘031 Patent ........................ 26 C. The ’031 Patent Is Valid ...............…infringe Novozymes’ U.S. Patent No. 6,867,031 for “Arnylase Variants” (“the ’031 Patent”), by their manufacture…led to many patentable inventions, including the alpha-amylase variants of the ’031 patent. These variants External link to document
2006-08-24 161 Findings of Fact & Conclusions of Law the claims of the ‘031 patent. (Compare id. at A-7734 with ‘031 patent, 65:10-66:19.) D. The Machius Reference… the ‘031 Patent ............................... 6 C. Prosecution History of the ‘031 Patent .........…infringement of U.S. Patent No. 6,867,031 (issued l\/|ar. 15, 2005) (the “‘031 patent”). Trial of this matter…, and 5 of the ‘031 patent, that those claims are valid, and that the ‘031 patent is enforceable Accordingly…the sole assignee of the ‘031 patent titled “Amylase Variants.” (‘031 patent.) 2. Genencor is a De|aware External link to document
2006-09-18 181 Tab 3, part 2 of 2 continued (2) 110:18, COPIES _106:15 137120 COMMUN!GAUONS 77 ..9 81 16 81:19 112:8 COPY¢ 25:20. 98:3, CLAR|F‘{ » 63:17…15 SPARAGRAPH - PATENT‘S - "!9:25 116:24 ONE » 8:7, 9:4, OPPOSE - 93:17 PATENTED » 10115, PERFECT…2005 17 April 2007 1:05-cv-00160 830 Patent None District Court, D. Delaware External link to document
2005-06-29 26 Exhibit Part 16 of 16 variants) US 6,143,708 (amylase mutants) ~ US 6,159,687 (method for generating recombined polynucleotides…/2005 Page 1 of 10 7 SEP 2004 13: 52 NOVOZYMES PATENTS . NO,5454 P. 25 C_ Fabret, S. Poncet, S. Danielsen…16 Filed 06/29/2005 Page3_of10 05:?2/ NOVOZYMES PATENTS 110_5464 p_ 27 Tori:en V. Bcn:hert, Ruben Abagyan…course TH|S NOTlCE OF ALLOWABlLlTY lS NOT A GRANT OF_PATENT RIGHTS. This application is subject to withdrawal… EXAM|NER'S AMENDMENT or NOTlCE OF lNFORMAL PATENT APPL|CATlON (PTO-i§?_) which gives reason(s) why External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.